Crackdown on Weight-Loss Drug Misuse, Centre Issues Legal Warning
The Centre has intensified its crackdown on the misuse and unauthorised sale of GLP-1 drugs, widely used for weight loss and Type 2 Diabetes, amid rising concerns over their easy availability online, in pharmacies, and at wellness clinics.
The Drug Controller General of India, along with State Drug Controllers, inspected 49 entities, including online pharmacies and clinics, issuing notices for violations. Authorities warned that non-compliance could lead to licence cancellation, fines, and legal action, stressing that such drugs cannot be sold over the counter, reports NDTV.
GLP-1 receptor agonists like semaglutide, liraglutide, and tirzepatide are effective but carry risks if misused. Side effects include nausea, dizziness, pancreatitis, kidney injury, bowel obstruction, and potential thyroid cancer. The government has also barred misleading advertisements promoting non-prescription use. Experts emphasise that while these drugs aid obesity and diabetes management, they must be used strictly under specialist supervision, alongside lifestyle changes like diet and exercise to ensure safety and effectiveness.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.